Deintensification of Treatment for Human Papillomavirus-related Oropharyngeal Cancer: Current State and Future Directions

Overview

Journal Oral Oncol

Publisher Elsevier

Specialty Dentistry

Date 2020 Apr 6

PMID 32247987

Citations 30

Authors

Elaine O Bigelow

Tanguy Y Seiwert

Carole Fakhry

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has emerged as a distinct clinical entity of head and neck cancer with expected high survival. This recognition has led to the investigation of whether a population of patients can be identified who can safely undergo treatment de-escalation, in an effort to minimize long-term treatment toxicity while maintaining excellent survival. The purpose of this review is to describe the rationale for treatment deintensification for HPV-related OPSCC, summarize available results from published clinical trials, explore the methods by which risk groups are assigned, and provide context for the multitude of clinical trials that are currently underway.

Citing Articles

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Mourtada J, Lony C, Nicol A, De Azevedo J, Bour C, Macabre C Front Immunol. 2023; 14:1264093.

PMID: 38022675 PMC: 10630910. DOI: 10.3389/fimmu.2023.1264093.

Assessment of Radiologic Extranodal Extension Using Combinatorial Analysis of Nodal Margin Breakdown and Metastatic Burden in Oropharyngeal Cancer.

Kim S, Park H, Yeou S, Roh J, Shin Y, Kim C Cancers (Basel). 2023; 15(13).

PMID: 37444387 PMC: 10339939. DOI: 10.3390/cancers15133276.

Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.

Canahuate G, Wentzel A, Mohamed A, van Dijk L, Vock D, Elgohari B Oral Oncol. 2023; 144:106460.

PMID: 37390759 PMC: 10561377. DOI: 10.1016/j.oraloncology.2023.106460.

Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes.

Eldridge R, Qin Z, Saba N, Houser M, Hayes D, Miller A Cancers (Basel). 2023; 15(12).

PMID: 37370794 PMC: 10296258. DOI: 10.3390/cancers15123184.

Transoral Surgery in HPV-Positive Oropharyngeal Carcinoma: Oncologic Outcomes in the Veterans Affairs System.

Faraji F, Kumar A, Voora R, Soliman S, Cherry D, Courtney P Laryngoscope. 2023; 134(1):207-214.

PMID: 37255050 PMC: 10687307. DOI: 10.1002/lary.30784.

References

Sovik A, Malinen E, Bruland O, Bentzen S, Olsen D . Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol. 2007; 52(2):499-513. DOI: 10.1088/0031-9155/52/2/013. View

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

Ma D, Price K, Moore E, Patel S, Hinni M, Garcia J . Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. J Clin Oncol. 2019; 37(22):1909-1918. PMC: 7098832. DOI: 10.1200/JCO.19.00463. View

Cohen E, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn M . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2018; 393(10167):156-167. DOI: 10.1016/S0140-6736(18)31999-8. View

Horne Z, Glaser S, Vargo J, Ferris R, Balasubramani G, Clump D . Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer. 2016; 122(13):2021-30. DOI: 10.1002/cncr.30021. View

ONeill C, Baxi S, Atoria C, ONeill J, Henman M, Sherman E . Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis. Cancer. 2015; 121(12):2083-9. PMC: 5018230. DOI: 10.1002/cncr.29262. View

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

Seiwert T, Foster C, Blair E, Karrison T, Agrawal N, Melotek J . OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2018; 30(2):297-302. DOI: 10.1093/annonc/mdy522. View

Marur S, Li S, Cmelak A, Gillison M, Zhao W, Ferris R . E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2016; 35(5):490-497. PMC: 5455313. DOI: 10.1200/JCO.2016.68.3300. View

10.

Rischin D, Young R, Fisher R, Fox S, Le Q, Peters L . Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 28(27):4142-8. PMC: 2953971. DOI: 10.1200/JCO.2010.29.2904. View

11.

Lin T, Garden A, Elhalawani H, Elgohari B, Jethanandani A, Ng S . Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019; 125(9):1536-1546. PMC: 7443173. DOI: 10.1002/cncr.31944. View

12.

Geltzeiler M, Bertolet M, Albergotti W, Gleysteen J, Olson B, Persky M . Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort. Oral Oncol. 2018; 84:82-87. PMC: 7745717. DOI: 10.1016/j.oraloncology.2018.07.013. View

13.

Maxwell J, Kumar B, Feng F, Worden F, Lee J, Eisbruch A . Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010; 16(4):1226-35. PMC: 2822887. DOI: 10.1158/1078-0432.CCR-09-2350. View

14.

Chera B, Amdur R, Green R, Shen C, Gupta G, Tan X . Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol. 2019; 37(29):2661-2669. PMC: 7010421. DOI: 10.1200/JCO.19.01007. View

15.

DSouza G, Westra W, Wang S, van Zante A, Wentz A, Kluz N . Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. JAMA Oncol. 2016; 3(2):169-177. PMC: 7286346. DOI: 10.1001/jamaoncol.2016.3067. View

16.

Weidhaas J, Harris J, Schaue D, Chen A, Chin R, Axelrod R . The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016; 3(4):483-491. PMC: 5470422. DOI: 10.1001/jamaoncol.2016.5478. View

17.

Ringash J . Survivorship and Quality of Life in Head and Neck Cancer. J Clin Oncol. 2015; 33(29):3322-7. DOI: 10.1200/JCO.2015.61.4115. View

18.

Fakhry C, Zevallos J, Eisele D . Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer. J Clin Oncol. 2017; 36(3):217-219. DOI: 10.1200/JCO.2017.75.2063. View

19.

OSullivan B, Huang S, Su J, Garden A, Sturgis E, Dahlstrom K . Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016; 17(4):440-451. DOI: 10.1016/S1470-2045(15)00560-4. View

20.

Beltz A, Gosswein D, Zimmer S, Limburg I, Wunsch D, Gribko A . Staging of oropharyngeal squamous cell carcinoma of the head and neck: Prognostic features and power of the 8th edition of the UICC staging manual. Eur J Surg Oncol. 2019; 45(6):1046-1053. DOI: 10.1016/j.ejso.2019.02.032. View